Akbari Zahra, Safari-Alighiarloo Nahid, Asadzadeh Aghdaei Hamid, Vahedi Mohsen, Montazer Haghighi Mahdi, Matani Borkheili Maryam, Nazemalhosseini-Mojarad Ehsan, Zali Mohammad Reza
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2020 Winter;13(1):23-30.
Our aim was to investigate the association between two single nucleotide polymorphisms (SNPs) of SMAD7 and the risk of CRC among Iranian individuals.
Genome-wide association studies (GWAS) have identified 18q21 as a risk locus for colorectal cancer (CRC), which maps to the SMAD7 gene.
This case-control study was conducted on 109 CRC cases and 109 controls in the Iranian population to evaluate the influence of two SNPs of SMAD7, rs2337106 and rs6507874, on the risk of CRC as well as on clinicopathological features. Genotype determination was performed by TaqMan assay via an ABI 7500 Real Time PCR System (Applied Biosystems) for the DNA of peripheral blood. Descriptive analysis and logistic regression model were used for statistical analyses.
Genotyping of the SNPs in the SMAD7 gene revealed that the frequency of G allele of rs2337106 was 53.7% in controls and 56.4% in cases (p-value=0.564) while the frequency of C allele of rs6507874 was 55.5% in controls and 56.3% in cases (p-value=0.772). Further, there were no significant differences in genotype frequencies of these SNPs between CRC patients and controls. The SMAD7 genotypes were not associated with the risk of CRC or with any clinicopathological characteristics such as tumor site, tumor grade, and stage TNM in CRC patients (p-value>0.05), even after adjustment for sex, age, and smoking status.
Our results provided the first evidence that SMAD7 genotypes, rs2337106 and rs6507874, could not be predisposing markers in genetic susceptibility to CRC in an Iranian population, at least in the studied population.
我们的目的是研究伊朗人群中SMAD7基因的两个单核苷酸多态性(SNP)与结直肠癌(CRC)风险之间的关联。
全基因组关联研究(GWAS)已将18q21确定为结直肠癌(CRC)的一个风险位点,该位点定位于SMAD7基因。
在伊朗人群中对109例CRC病例和109例对照进行了这项病例对照研究,以评估SMAD7基因的两个SNP,即rs2337106和rs6507874,对CRC风险以及临床病理特征的影响。通过TaqMan分析,利用ABI 7500实时荧光定量PCR系统(应用生物系统公司)对外周血DNA进行基因型测定。采用描述性分析和逻辑回归模型进行统计分析。
SMAD7基因SNP的基因分型显示,rs2337106的G等位基因频率在对照组中为53.7%,在病例组中为56.4%(p值 = 0.564),而rs6507874的C等位基因频率在对照组中为55.5%,在病例组中为56.3%(p值 = 0.772)。此外,CRC患者与对照组之间这些SNP的基因型频率没有显著差异。即使在对性别、年龄和吸烟状况进行调整后,SMAD7基因型与CRC风险或CRC患者的任何临床病理特征(如肿瘤部位、肿瘤分级和TNM分期)均无关联(p值>0.05)。
我们的结果首次证明,至少在所研究的伊朗人群中,SMAD7基因型rs2337106和rs6507874不是CRC遗传易感性的易感标记。